(RTTNews) - Tectonic Therapeutic Inc. (TECX), a clinical-stage biotechnology company, on Thursday announced positive interim data from its ongoing Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction.
The interim analysis showed that TX45 resulted in a 17.9 percent reduction in pulmonary capillary wedge pressure or PCWP and over a 30 percent reduction in pulmonary vascular resistance or PVR in patients with combined pre- and post-capillary pulmonary hypertension or CpcPH, a subgroup with more severe disease. These improvements in both left ventricular function and pulmonary hemodynamics demonstrate TX45's potential as a promising treatment for PH-HFpEF, a condition currently lacking approved therapies.
Importantly, TX45 was well tolerated, with no serious adverse events or significant hypotension reported.
The ongoing APEX Phase 2 trial is expected to further evaluate TX45 in a similar patient population, with topline data anticipated in 2026.
Tectonic's CEO, Dr. Alise Reicin, highlighted the importance of these results, noting that TX45's dual effects on left ventricular function and pulmonary hemodynamics could significantly improve outcomes for PH-HFpEF patients.
TECX closed Wednesday's (Jan.29 2025) trading at $25.72 up by 5.24%. In premarket trading Thursday the stock is up 45.14% at $37.33.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
